Table 2.

Demographic and symptom ratings at baseline for all schizophrenia patients and for patients in each drug group.

	All Subjects	Risperidone	Olanzapine	Haloperidol
N	51	19	21	11
Gender (M:F)	43:8	15:4	17:4	11:0
Ethnicity (C:AA)*	46%:54%	29%:71%	65%:35%	36%:64%
Baseline A/C/O**	30/15/6	12/6/1	12/6/3	6/3/2
PK/AD/MS***	8/19/7	1/8/2	4/8/4	3/3/1
Age	48.8 (7.5)	46.8 (8.3)	49.8 (7.2)	50.3 (6.2)
Education	12.6 (2.4)	12.5 (1.6)	12.2 (3.0)	13.2 (2.4)
BPRS Positive	2.5 (1.0)	2.4 (1.0)	2.3 (1.0)	3.1 (.91)
BPRS Negative	2.3 (.8)	2.3 (.8)	2.3 (.8)	2.1 (.9)

^*Percent: Caucasian (C), African American (AA);

^**Number of subjects on atypcial (A), conventional (C), or other (O) antipsychotic medication at baseline;

^***Number of subjects on antiparkinsonion (PK), antidepressant (AD), or mood stabilizer (MS) medications at baseline